Sarah E. M. Herman

4.4k citations

42 papers · 2.5k indexed · 1 hit paper · h-index 19

Genetics top 0.2%
Pathology and Forensic Medicine top 0.5%
Immunology top 2%
Hematology top 2%
Molecular Biology

Co-authors: Adrian Wiestner Mohammed Farooqui Joseph J. Buggy John C. Byrd Amy J. Johnson Asha Ramanunni Rashida Z. Mustafa Jeffrey J. Jones
Topics: Chronic Lymphocytic Leukemia Research (41 papers)Lymphoma Diagnosis and Treatment (27 papers)Chronic Myeloid Leukemia Treatments (11 papers)
Cited by: Genetics Pathology and Forensic Medicine Hematology
Journals: Blood Cancer Research Clinical Cancer Research
Partner nations: United States Spain Denmark

In The Last Decade

Sarah E. M. Herman

41 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

2011 607 citations Sarah E. M. Herman, Amber Gordon et al. Blood profile →

Peers

Countries citing papers authored by Sarah E. M. Herman

Since Specialization

Citations

This map shows the geographic impact of Sarah E. M. Herman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah E. M. Herman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah E. M. Herman more than expected).

Fields of papers citing papers by Sarah E. M. Herman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah E. M. Herman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah E. M. Herman. The network helps show where Sarah E. M. Herman may publish in the future.

Co-authorship network of co-authors of Sarah E. M. Herman

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah E. M. Herman. A scholar is included among the top collaborators of Sarah E. M. Herman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah E. M. Herman. Sarah E. M. Herman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage 2021 ·Leukemia & lymphoma ·Arshia Soleimani,Alba Navarro,Delong Liu,Sarah E. M. Herman,Shih‐Sung Chuang,Irma Slavutsky,Marina Narbaitz,Hana Safah,John Schmieg,John J. Lefante,Mark Roschewski,Wyndham H. Wilson,Adrian Wiestner,Nakhle S. Saba	2
2	TLR Signaling Is Activated in Lymph Node–Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib 2018 ·Cancer Research ·Eman L. Dadashian,Erin M. McAuley,Delong Liu,Arthur L. Shaffer,Ryan M. Young,(unknown),Michael J. Kruhlak,Louis M. Staudt,Adrian Wiestner,Sarah E. M. Herman	44
3	Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model 2017 ·Clinical Cancer Research ·Carsten Utoft Niemann,Helena Mora-Jensen,Eman L. Dadashian,Fanny Krantz,Todd Covey,Shih‐Shih Chen,Nicholas Chiorazzi,Raquel Izumi,Roger G. Ulrich,Brian J. Lannutti,Adrian Wiestner,Sarah E. M. Herman	25
4	MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia 2017 ·Cancer Research ·Nakhle S. Saba,Deanna H. Wong,(unknown),(unknown),Patricia Lobelle‐Rich,Eman L. Dadashian,Delong Liu,Lorena Fontán,Erik K. Flemington,Cydney Nichols,Chingiz Underbayev,Hana Safah,Ari Melnick,Adrian Wiestner,Sarah E. M. Herman	40
5	Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood 2017 ·Leukemia ·Thomas M. Herndon,(unknown),Nakhle S. Saba,Janet Valdez,Claire Emson,Michelle Gatmaitan,Xin Tian,Thomas E. Hughes,Clare Sun,D Arthur,Maryalice Stetler‐Stevenson,Christina M. Yuan,Carsten Utoft Niemann,Gerald E. Marti,Georg Aue,S. Soto,Mohammed Farooqui,Sarah E. M. Herman,Nicholas Chiorazzi,Adrian Wiestner	88
6	Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib 2017 ·Blood ·Clare Sun,Camilia Soof,(unknown),Sarah E. M. Herman,Erika M. Cook,Kyle A. Udd,Haiming Chen,Eric Sanchez,Xin Tian,Inhye E. Ahn,James R. Berenson,Adrian Wiestner	2
7	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia 2016 ·Clinical Cancer Research ·Sarah E. M. Herman,Arnau Montraveta,Carsten Utoft Niemann,Helena Mora-Jensen,Michael Gulrajani,Fanny Krantz,Rose Mantel,Lisa L. Smith,Fabienne McClanahan,Bonnie K. Harrington,Dolors Colomer,Todd Covey,John C. Byrd,Raquel Izumi,Allard Kaptein,Roger G. Ulrich,Amy J. Johnson,Brian J. Lannutti,Adrian Wiestner,Jennifer A. Woyach	121
8	Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma 2016 ·Blood ·Nakhle S. Saba,Delong Liu,Sarah E. M. Herman,Chingiz Underbayev,Xin Tian,(unknown),Marc A. Weniger,Martin Skarzynski,(unknown),Lorena Fontán,Ari Melnick,Clíona Grant,Mark Roschewski,Alba Navarro,Sı́lvia Beà,Stefania Pittaluga,Kieron Dunleavy,Wyndham H. Wilson,Adrian Wiestner	111
9	Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade 2016 ·Seminars in Oncology ·Sarah E. M. Herman,Adrian Wiestner	19
10	Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia 2016 ·Leukemia ·(unknown),(unknown),Sarah E. M. Herman,Nakhle S. Saba,(unknown),(unknown),(unknown),Mahfooz Farooqui,Clare Sun,Sara M. Sarasua,Zhen Zhao,(unknown),Osama Elbaz,(unknown),Adrian Wiestner,Katherine R. Calvo	32
11	Abstract 4797: The combination of ACP-196 and ACP-319 leads to increased survival in the TCL1-192 CLL mouse model 2016 ·Cancer Research ·Helena Mora-Jensen,Carsten Utoft Niemann,Michael Gulrajani,Fanny Krantz,Todd Covey,Brian J. Lannutti,Adrian Wiestner,Sarah E. M. Herman	1
12	Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo 2015 ·Clinical Cancer Research ·Sarah E. M. Herman,Rashida Z. Mustafa,Jade Jones,Deanna H. Wong,Mohammed Farooqui,Adrian Wiestner	91
13	Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study 2015 ·Clinical Cancer Research ·Carsten Utoft Niemann,Sarah E. M. Herman,Irina Marić,Julio Gómez‐Rodríguez,Angélique Biancotto,Betty Chang,Sabrina Martyr,Maryalice Stetler‐Stevenson,Constance M. Yuan,Katherine R. Calvo,Raul C. Braylan,Janet Valdez,Yuh Shan Lee,Deanna H. Wong,Jade Jones,Clare Sun,Gerald E. Marti,Mohammed Farooqui,Adrian Wiestner	160
14	Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy 2015 ·Clinical Cancer Research ·Martin Skarzynski,Carsten Utoft Niemann,Yuh Shan Lee,Sabrina Martyr,Irina Marić,Dalia Salem,Maryalice Stetler‐Stevenson,Gerald E. Marti,Katherine R. Calvo,Constance M. Yuan,Janet Valdez,Susan Soto,Mohammed Farooqui,Sarah E. M. Herman,Adrian Wiestner	62
15	Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study 2014 ·Leukemia ·Sarah E. M. Herman,Carsten Utoft Niemann,Mahfooz Farooqui,Jeffrey A. Jones,Rashida Z. Mustafa,Andrew Lipsky,Nakhle S. Saba,Sabrina Martyr,S. Soto,Joseph M. Valdez,(unknown),I. Maric,Katherine R. Calvo,Lone Bredo Pedersen,Geisler Ch,Danping Liu,Gerald E. Marti,Georg Aue,Adrian Wiestner	131
16	Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients 2013 ·Blood ·Betty Chang,Michelle Francesco,Martin F. M. de Rooij,Padmaja Magadala,Susanne Steggerda,Min Huang,Annemieke Kuil,Sarah E. M. Herman,Stella Chang,Steven T. Pals,Wyndham H. Wilson,Adrian Wiestner,Marcel Spaargaren,Joseph J. Buggy,Laurence Elias	159
17	Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy 2013 ·Leukemia ·Sarah E. M. Herman,Ellen X. Sun,Erin M. McAuley,Matthew M. Hsieh,Stefania Pittaluga,Mark Raffeld,Danping Liu,Keyvan Keyvanfar,Chris Chapman,Jianjun Chen,Joseph J. Buggy,Georg Aue,John F. Tisdale,Patricia Pérez‐Galán,Adrian Wiestner	64
18	Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways 2013 ·Blood ·Sarah E. M. Herman,Rashida Z. Mustafa,Sabrina Martyr,(unknown),Janet Valdez,Susan Soto,Mohammed Farooqui,Adrian Wiestner	0
19	Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765breakdown → 2011 ·Blood ·Sarah E. M. Herman,Amber Gordon,Erin Hertlein,Asha Ramanunni,Xiaoli Zhang,Samantha Jaglowski,Joseph M. Flynn,Jeffrey J. Jones,Kristie A. Blum,Joseph J. Buggy,Ahmed Hamdy,Amy J. Johnson,John C. Byrd	607
20	The NSG – Human CLL Xenograft Model Recapitulates the Human Lymph Node Microenvironment in Regards to B-Cell Activation and Tumor Proliferation 2011 ·Blood ·Ellen X. Sun,Sarah E. M. Herman,Matthew M. Hsieh,John F. Tisdale,Jichun Chen,Georg Aue,Patricia Pérez‐Galán,Adrian Wiestner	1

About Sarah E. M. Herman

Sarah E. M. Herman is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology, having authored 42 papers that have together received 2.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (41 papers), Lymphoma Diagnosis and Treatment (27 papers) and Chronic Myeloid Leukemia Treatments (11 papers). The work is most often cited by research in Genetics (2.1k citations), Pathology and Forensic Medicine (1.6k citations) and Hematology (574 citations). Sarah E. M. Herman has collaborated with scholars based in United States, Spain and Denmark. Frequent co-authors include Adrian Wiestner, Mohammed Farooqui, Joseph J. Buggy, John C. Byrd, Amy J. Johnson, Asha Ramanunni, Rashida Z. Mustafa, Jeffrey J. Jones, Kristie A. Blum and Ahmed Hamdy. Their work appears in journals such as Blood, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact